Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Resource Type
Article
Authors
Petrylak, Daniel P. ; Ratta, Raffaele ; Matsubara, Nobuaki ; Korbenfeld, Ernesto Pablo ; Gafanov, Rustem ; Mourey, Loic ; Todenhöfer, Tilman ; Gurney, Howard ; Kramer, Gero ; Bergman, Andre M. ; Zalewski, Pawel ; De Santis, Maria ; Armstrong, Andrew J. ; Gerritsen, Winald R. ; Pachynski, Russell Kent ; Saretsky, Todd L. ; Ghate, Sameer R. ; Li, Xin Tong ; Schloss, Charles ; Fizazi, Karim
Source
Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, p129-129, 1p
Subject
Language
ISSN
0732183X